It is clinically routine to treat neovascular age-related macular degeneration by intravitreal injection of anti-VEGF antibodies (i.e., Avastin and Lucentis), which are nominally 150 kDa.15 The gene discussed is VEGFA; the disease is wet macular degeneration.